Biological Characteristics And Therapeutic Effect Of Acute Erytho-Leukemia

Purpose:The objective was to observe the biological characteristic and the therapeutic effect in patients with acute erythroleukemia (AML-M6).Method : 1.29 patients of acute erythroleukemia (AML-M6),from Jan.1995 to June.2005 in Wuhan Union Hospital ,were selected as investigation objective, including 19 male and 10 female, from 7 to 68 years old. The median age was 43 years old. 30 patients of AML-M2a in the same hospital at the same time were selected as contrast, including male 18 and female 12, from 13 to 77 years old, the median age was 35 years old. 20 patients of M1, 15 patients of M3, 15 patients of M4 and M5 were compared with patients of M6 in the aspect of expression of Gly-A frequency.2. All the patients were received bone marrow aspiration cytology, immunophenotype and some patients were received cytogenetic examination.3. The data of patients were reviewed, including results of bone marrow aspiration cytology, immunophenotype, cytogenetic examination, and chemotherapy. The differences between the investigation and the contrast were studied to reveal the biological characteristic and the therapeutic effect in patients of M6.Results:①There were immature cells (2%~10%) and erythroblast in peripheral blood of M6. Myelodysplastic features involving multiple haemopoietic lineages in bone marrow of 19 patients in M6 was higher than that of 2 patients in M2.②Flow cytometry indicated the expression of Gly-A frequency was significant more common in M1, M2a, M3, M4 and M5 (p<0.01).③The expression frequency of HLA-DR (60.00±24.79 % ), CD34 (40.00±24.79%), CD38 (33.33±23.86%) in M6 were common as well, the expression frequency of myeloid immunophenotypes CD13 (66.67±23.86%), MPO (33.33±23.86%), CD33 (46.67±25.25%), CD15 (33.33±23.86%), CD117 (46.67±25.25%) were common in M6. Lymphocytic immunophenotypes CD3, CD4, CD19 expressed in a part of patients with M6 and the expression of CD4 frequency was common (26.67%).④The expression frequency of CD38, CD33, CD15, MPO in M6 were less common than in M2 (P<0.01).⑤4 patients in 9 were chromosomal abnormal and abnormatility was 44.44%, one of them was complex chromosomal abnormal.⑥The complete ression rate of M6 was 29.41%, it was lower than M2 (P<0.01).⑦The difference of expression of Gly-A frequency between M6a(58.82%) and M6b(75%) had not statistical meaning. The difference of clinical therapeutic response of M6a(41.18%) had not statistical meaning of M6b(16.67%).Conclusion:M6 has its own biologic features:①The rate of multiple haemopoietic lineages in bone marrow is higher in M6.②Gly-A is sepecific immunophentype in M6, it can help diffentiating M6 from other acute myeloid leukemia types.③M6 has poor clinical therapeutic response.